Integrated Filing- Financial

Windlas Biotech Limited has released its consolidated unaudited financial results for the quarter and nine months ending December 31, 2024. The company reported revenue from operations of ₹1,950.19 crore, reflecting a notable year-on-year increase from ₹1,622.13 crore.

Total expenses rose to ₹1,787.88 crore, leading to a profit before tax of ₹203.38 crore.

With an overall profit of ₹155.76 crore for the quarter, this indicates stable financial health amidst rising operational scaling.

Investors may view this as a positive outlook, suggesting solid growth potential in the pharmaceutical sector while keeping an eye on cost management.